TCF: Avammune Therapeutics attending the IO360 Conference February 2020 in New York

---

SITC: Avammune Therapeutics team attending the Society for Immunotherapy for Cancer 2019 Annual Meeting.

---

Immuno-Oncology Summit: Avammune Therapeutics STING modulator program presented at Immunooncology Summit Boston 2019.

---

PRWeb: Avammune Therapeutics announces Series A funding and formation of Scientific Advisory Board.

---

Bangalore Mirror Bureau: These two collegemates are making drugs for rare diseases that afflict mostly children.

---

Forbes India: Tackling pharma's rare challenges - Those afflicted by orphan diseases are rare; companies looking for orphan drugs are rarer still. Among them is Aten Porus that has found early success in this uncharted region of medical science.

---

BW: Oraxion executes an Exclusive Option Agreement on ORX-301 for treating NPC and FSGS with the potential to reach over US$125 million in payments. (We would like to dedicate this milestone in memory of our recently departed friend and colleague Soniya Johny who was instrumental in bringing this work to fruition).

---

YourStory: This Purdue University grad aims to find drugs for rare genetic disorders.

---

ET Bureau: Aten Porus Lifesciences: Firm is developing drugs to fight a host of rare diseases globally. To begin with, the duo decided to focus on Niemann-Pick Type C (NPC) disorder that’s also referred to as Childhood Alzheimer’s.

---